ReviewJournal of the Royal Society of New Zealand2025
Challenges and opportunities for Aotearoa/New Zealand's breast screening programme.
Review in Journal of the Royal Society of New Zealand, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Around 3500 New Zealand women will be diagnosed with breast cancer each year. Of these, 45% will be diagnosed through mammography screening, either through BreastScreen Aotearoa or through the private sector. Those diagnosed through screening have better outcomes and importantly more equitable outcomes for Māori and Pacific women. With the advent of many technological changes, there are opportunities to increase the proportion of women who are diagnosed early through systematic screening and thus improve overall mortality from breast cancer. This article discusses the potential opportunities including widening the screening age and addressing the differences in screening rates for Māori and other ethnicities. The review also discusses potential changes to the screening modality (mammography), the value of grading breast density and the use of personalised screening. Finally, the article addresses the potential uses of Artificial Intelligence in assessing risk of cancer and in improving diagnostic accuracy of mammography.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.